Collectively, these data suggest that a concomitant combination of cMET inhibitors and ICIs, or a sequential combination of cMET inhibitors followed by ICIs, may improve responses to cancer immunotherapy on multiple fronts in mUM patients. The gene discussed is MET; the disease is cancer.